Get the Stockscreener App
0.25
78.07%
-0.89
After Hours:
.25
Trevena Inc stock is traded at $0.25, with a volume of 1,076.
It is down -78.07% in the last 24 hours and down -78.07% over the past month.
See More
Previous Close:
$1.14
Open:
$0.25
24h Volume:
1,076
Relative Volume:
9.34
Market Cap:
$N/A
Revenue:
$3.13M
Net Income/Loss:
$-40.29M
P/E Ratio:
-0.0781
EPS:
-3.2
Net Cash Flow:
$-33.08M
1W Performance:
-78.07%
1M Performance:
-78.07%
6M Performance:
+427.32%
1Y Performance:
+221.67%
1-Day Range:
$0.25
$0.25
1-Week Range:
$0.25
$0.25
52-Week Range:
$0.25
$1.15
Trevena Inc Stock (TRVN) Company Profile
Compare TRVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
0.25 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-21 | Initiated | Oppenheimer | Perform |
| Sep-14-20 | Initiated | Guggenheim | Buy |
| Aug-28-20 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-19 | Resumed | H.C. Wainwright | Buy |
| Nov-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-12-18 | Downgrade | Needham | Buy → Hold |
| Oct-10-18 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-17 | Reiterated | Needham | Buy |
| Oct-16-17 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-12-17 | Reiterated | H.C. Wainwright | Buy |
| May-08-17 | Reiterated | Needham | Buy |
| Feb-23-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Reiterated | FBR & Co. | Outperform |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-09-17 | Initiated | H.C. Wainwright | Buy |
| Jan-05-17 | Initiated | Oppenheimer | Outperform |
| May-17-16 | Reiterated | FBR Capital | Outperform |
| May-17-16 | Reiterated | Needham | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Sep-01-15 | Reiterated | Wedbush | Outperform |
| Aug-03-15 | Initiated | Brean Capital | Buy |
View All
Trevena Inc Stock (TRVN) Latest News
BRIEF-Amara Holdings To Be Delisted From SGX-St Mainboard - Yahoo.co
Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board - GlobeNewswire
Aegle Therapeutics Names Scott Braunstein, M.D. as Chairman of the Board - citybiz
Is Trevena, Inc. overvalued or undervalued? - MarketsMojo
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors - GlobeNewswire
Trevena (NASDAQ:TRVN) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm - ACCESS Newswire
Acute Pain Drug Pipeline Analysis: Market Overview, Trends, and Future Growth (2034) - openPR.com
Trevena to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail
Opioid Drugs Market in 2025-2032 Detailed Study Analysis with - openPR.com
Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World
Behind the Booth at InfoComm 2025: An Interview With tvONE’s Mark Trevena - rAVe [PUBS]
Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $50,000 Encouraged to Contact the Firm - ACCESS Newswire
COVID-19 Therapeutics Market Current Scenario with Future Aspect Analysis - openPR.com
Opioid Drugs Market: Investment Analysis & Growth Opportunity - openPR.com
Highest-Paid CEOs2024 - AFL-CIO
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aviation Co. Says Workers' Class Action Too Broad - Law360
Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
North American Morning Briefing : Stock Futures -2- - MarketScreener
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com
Trevena Delays Yearly Report Filing - TipRanks
Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech
Ten option delistings on March 24th - TipRanks
Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter
Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena, Inc. to Host Earnings Call - ACCESS Newswire
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World
Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR
Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World
Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks
Trevena Inc Stock (TRVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.08%
Cap:
|
Volume (24h):